Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews Protocol - Intervention

Intermittent versus continuous systemic therapy as treatment for unresectable metastatic colorectal cancer

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Non‐inferiority interpretation of meta‐analysis findings
Figures and Tables -
Figure 2

Non‐inferiority interpretation of meta‐analysis findings

Planned subgroup analysis
Figures and Tables -
Figure 3

Planned subgroup analysis

Table 1. Table 1

Table 1. Examples of intermittent versus continuous treatment schemes

1.

Intermittent: FOLFOX17, 12 weeks; sLV5‐FU22, 24 weeks; FOLFOX7, 12 weeks

Continuous: FOLFOX4 every 2 weeks until progression of disease (PD) (Tournigand 2004)

2.

Intermittent: FOLFIRI3, 12 weeks; chemotherapy‐Free‐Interval (CFI); restart FOLFIRI at PD

Continuous: FOLFIRI, 24 weeks (Alexopoulos 2006)

3.

Intermittent: Bevacizumab + capecitabine/oxaliplatin, 18 weeks; CFI; restart Bevacizumab+ capecitabine/oxaliplatin at PD

Continuous: Bevacizumab + capecitabine/oxaliplatin, 18 weeks; bevacizumab+capecitabine, restart bevacizumab+capecitabine/oxaliplatin at PD (Simkens 2015)

1 FOLFOX: FOL: folinic acid; F: fluorouracil (5‐FU); OX: oxaliplatin.
2 sLV5‐FU2: simplified leucovorin plus bolus and infusional fluorouracil.
3 FOLFIRI: FOL: folinic acid; F: fluorouracil (5‐FU); IRI: irinotecan.

Figures and Tables -
Table 1. Table 1